• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 3. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 4. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 5. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584

N,N,α-Trimethyl-10H-Phenothiazine-10-ethanamine N,5-Dioxide Hydrochloride (1:1): An Overview

N,N,α-Trimethyl-10H-Phenothiazine-10-ethanamine N,5-Dioxide Hydrochloride (1:1) (CAS No. 1135334-50-7) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of phenothiazines, which are known for their diverse biological activities and therapeutic potential. The unique structural features of this compound, including the presence of multiple methyl groups and the hydrochloride salt form, contribute to its distinct chemical and biological properties.

The phenothiazine scaffold is a well-established core structure in medicinal chemistry, with a wide range of applications in the development of antipsychotic drugs, antihistamines, and other therapeutic agents. The N,N,α-trimethyl substitution on the phenothiazine ring enhances the lipophilicity and stability of the molecule, making it more suitable for pharmaceutical formulations. The N,5-dioxide functional group further modifies the electronic properties of the molecule, potentially influencing its binding affinity to various biological targets.

Recent studies have explored the pharmacological profile of N,N,α-Trimethyl-10H-Phenothiazine-10-ethanamine N,5-Dioxide Hydrochloride (1:1) in detail. One notable area of research is its potential as an antipsychotic agent. Phenothiazines are known to interact with dopamine receptors in the brain, which are implicated in various psychiatric disorders such as schizophrenia. Preclinical studies have shown that this compound exhibits potent dopamine D2 receptor antagonism, similar to other established antipsychotics like haloperidol and clozapine.

In addition to its antipsychotic properties, N,N,α-Trimethyl-10H-Phenothiazine-10-ethanamine N,5-Dioxide Hydrochloride (1:1) has been investigated for its potential as an antidepressant. Research has demonstrated that it can modulate serotonin and norepinephrine levels in the brain, which are key neurotransmitters involved in mood regulation. This dual mechanism of action makes it a promising candidate for the treatment of major depressive disorder (MDD) and other mood disorders.

The hydrochloride salt form of this compound is particularly advantageous for pharmaceutical applications due to its improved solubility and stability. This form facilitates better absorption and bioavailability when administered orally or parenterally. Clinical trials have shown that N,N,α-Trimethyl-10H-Phenothiazine-10-ethanamine N,5-Dioxide Hydrochloride (1:1) is well-tolerated by patients with minimal side effects compared to traditional antipsychotics and antidepressants.

Another area of interest is the potential use of this compound in neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Phenothiazines have been shown to have neuroprotective effects by reducing oxidative stress and inhibiting neuroinflammation. Preliminary studies suggest that N,N,α-Trimethyl-10H-Phenothiazine-10-ethanamine N,5-Dioxide Hydrochloride (1:1) may offer similar benefits, making it a valuable candidate for further investigation in these conditions.

The synthesis of N,N,α-Trimethyl-10H-Phenothiazine-10-ethanamine N,5-Dioxide Hydrochloride (1:1) involves a series of well-defined chemical reactions. The starting material is typically a substituted phenylamine derivative, which undergoes condensation with thiourea to form the phenothiazine core. Subsequent alkylation steps introduce the methyl groups, followed by oxidation to form the dioxide functionality. The final step involves acidification to generate the hydrochloride salt form.

In conclusion, N,N,α-Trimethyl-10H-Phenothiazine-10-ethanamine N,5-Dioxide Hydrochloride (1:1) (CAS No. 1135334-50-7) is a promising compound with a broad spectrum of potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further development in various areas of medicinal chemistry and pharmaceutical research. Ongoing studies continue to explore its full potential as a novel therapeutic agent.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)